Protein hydrolyzates, animal

Endpoint summary

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records

Reference

Endpoint:

sub-chronic toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

other: OECD Guideline but not TG indicated.

Principles of method if other than guideline:

The study was conducted in compliance with the good laboratory practices (US FDA, 1987), and in accordance with OECD guidelines (OECD, 1987) at Product Safety Laboratories (Dayton, NJ, USA). One group of males and one group of females were assigned to one of the four treatments: control (distilled water), low dose (30 mg test product/kg/day), intermediate dose (300 mg test product/kg/day), or high dose (1000 mg
test product/kg/day). The human exposure to the test substance, based on the label recommendation found in the dietary ‘‘supplement facts’’ panel, was up to 30 mg/kg/day. Thus, the dose levels selected for this study corresponded to 0, 1, 10, and 33 times the expected human exposure level. The highest level (33 times) is considered as a regulatory limit dose for rats and was expected to exhibit some evidence of toxicity. A NOAEL was expected at 300 mg/kg/day.
The individual doses of the test product were determined based on each animal body weight and prepared within 2 h of administration as a 0.6% (low), 6.0% (intermediate), and 20% (high) w/v solution in distilled water. All doses were volumetrically equal (100 mL) and administered orally using a stainless steel ball-tipped gavage needle attached to a syringe.
The dose administration was performed at the same time each day (± 2 h) for 92 (males) or 93 (females) consecutive days. The control animals received distilled water at the same volume (100 mL) as the test groups.

GLP compliance:

yes

Limit test:

no

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Route of administration:

oral: gavage

Vehicle:

unchanged (no vehicle)

Analytical verification of doses or concentrations:

yes

Duration of treatment / exposure:

90 days

Frequency of treatment:

dayly

Remarks:

Doses / Concentrations:
20% (high) w/v
Basis:
nominal in water

Remarks:

Doses / Concentrations:
6.0% w/v (intermediate)
Basis:
nominal in water

Remarks:

Doses / Concentrations:
0.6% w/v (low)
Basis:
nominal in water

No. of animals per sex per dose:

40 males and 40 females total.
10 males and 10 females per dose

Control animals:

yes

Key result

Dose descriptor:

NOAEL

Effect level:

> 1 000 mg/kg bw/day (nominal)

Sex:

male/female

Basis for effect level:

mortality

Critical effects observed:

not specified

There was no mortality, adverse effects or clinical signs of toxicity during the study associated with the treatment.

One male from the intermediate dose group was euthanized on day 38 after the animal was found moribund. Postmortem analysis revealed a red discharge from the animal’s eyes and nose, nasal swelling, crooked or broken teeth, and minimal stomach content. These symptoms indicated an injury sustained in the cage and were not related to the treatment.

Male and female animals treated with the test substance had an average body weight and average body weight gain comparable to those from the control group.

Conclusions:

A GLP, OCDE Guideline study indicates a NOAEL higher that 1.000 mg/Kw bw

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

NOAEL

1 000 mg/kg bw/day

Study duration:

subchronic

Species:

rat

Repeated dose toxicity: inhalation - systemic effects

Link to relevant study records

Reference

Endpoint:

short-term repeated dose toxicity: inhalation

Data waiving:

other justification

Justification for data waiving:

other:

Repeated dose toxicity: inhalation - local effects

Link to relevant study records

Reference

Endpoint:

short-term repeated dose toxicity: inhalation

Data waiving:

other justification

Justification for data waiving:

other:

Repeated dose toxicity: dermal - systemic effects

Link to relevant study records

Reference

Endpoint:

short-term repeated dose toxicity: dermal

Data waiving:

other justification

Justification for data waiving:

other:

Repeated dose toxicity: dermal - local effects

Link to relevant study records

Reference

Endpoint:

short-term repeated dose toxicity: dermal

Data waiving:

other justification

Justification for data waiving:

other: